1. Home
  2. BAFN vs SGMT Comparison

BAFN vs SGMT Comparison

Compare BAFN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAFN
  • SGMT
  • Stock Information
  • Founded
  • BAFN 1999
  • SGMT 2006
  • Country
  • BAFN United States
  • SGMT United States
  • Employees
  • BAFN N/A
  • SGMT N/A
  • Industry
  • BAFN Savings Institutions
  • SGMT
  • Sector
  • BAFN Finance
  • SGMT
  • Exchange
  • BAFN Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • BAFN 65.2M
  • SGMT 71.2M
  • IPO Year
  • BAFN N/A
  • SGMT 2023
  • Fundamental
  • Price
  • BAFN $15.63
  • SGMT $3.64
  • Analyst Decision
  • BAFN
  • SGMT Strong Buy
  • Analyst Count
  • BAFN 0
  • SGMT 6
  • Target Price
  • BAFN N/A
  • SGMT $25.67
  • AVG Volume (30 Days)
  • BAFN 6.6K
  • SGMT 392.3K
  • Earning Date
  • BAFN 07-24-2025
  • SGMT 05-08-2025
  • Dividend Yield
  • BAFN 1.96%
  • SGMT N/A
  • EPS Growth
  • BAFN 113.18
  • SGMT N/A
  • EPS
  • BAFN 2.34
  • SGMT N/A
  • Revenue
  • BAFN $80,167,000.00
  • SGMT N/A
  • Revenue This Year
  • BAFN N/A
  • SGMT N/A
  • Revenue Next Year
  • BAFN N/A
  • SGMT N/A
  • P/E Ratio
  • BAFN $6.97
  • SGMT N/A
  • Revenue Growth
  • BAFN 2.60
  • SGMT N/A
  • 52 Week Low
  • BAFN $11.00
  • SGMT $1.73
  • 52 Week High
  • BAFN $19.75
  • SGMT $7.38
  • Technical
  • Relative Strength Index (RSI)
  • BAFN 52.13
  • SGMT 57.81
  • Support Level
  • BAFN $14.79
  • SGMT $3.18
  • Resistance Level
  • BAFN $16.35
  • SGMT $3.85
  • Average True Range (ATR)
  • BAFN 0.41
  • SGMT 0.27
  • MACD
  • BAFN 0.11
  • SGMT 0.01
  • Stochastic Oscillator
  • BAFN 61.08
  • SGMT 61.04

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: